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Summary
Background The prevalence of epilepsy in sub-Saharan Africa seems to be higher than in other parts of the world, but 
estimates vary substantially for unknown reasons. We assessed the prevalence and risk factors of active convulsive 
epilepsy across ﬁ ve centres in this region. 
Methods We did large population-based cross-sectional and case-control studies in ﬁ ve Health and Demographic 
Surveillance System centres: Kiliﬁ , Kenya (Dec 3, 2007–July 31, 2008); Agincourt, South Africa (Aug 4, 2008–Feb 27, 
2009); Iganga-Mayuge, Uganda (Feb 2, 2009–Oct 30, 2009); Ifakara, Tanzania (May 4, 2009–Dec 31, 2009); and 
Kintampo, Ghana (Aug 2, 2010–April 29, 2011). We used a three-stage screening process to identify people with active 
convulsive epilepsy. Prevalence was estimated as the ratio of conﬁ rmed cases to the population screened and was 
adjusted for sensitivity and attrition between stages. For each case, an age-matched control individual was randomly 
selected from the relevant centre’s census database. Fieldworkers masked to the status of the person they were 
interviewing administered questionnaires to individuals with active convulsive epilepsy and control individuals to 
assess sociodemographic variables and historical risk factors (perinatal events, head injuries, and diet). Blood samples 
were taken from a randomly selected subgroup of 300 participants with epilepsy and 300 control individuals from 
each centre and were screened for antibodies to Toxocara canis, Toxoplasma gondii, Onchocerca volvulus, Plasmodium 
falciparum, Taenia solium, and HIV. We estimated odds ratios (ORs) with logistic regression, adjusted for age, sex, 
education, employment, and marital status.
Results 586 607 residents in the study areas were screened in stage one, of whom 1711 were diagnosed as having active 
convulsive epilepsy. Prevalence adjusted for attrition and sensitivity varied between sites: 7·8 per 1000 people (95% CI 
7·5–8·2) in Kiliﬁ , 7·0 (6·2–7·4) in Agincourt, 10·3 (9·5–11·1) in Iganga-Mayuge, 14·8 (13·8–15·4) in Ifakara, and 
10·1 (9·5–10·7) in Kintampo. The 1711 individuals with the disorder and 2032 control individuals were given 
questionnaires. In children (aged <18 years), the greatest relative increases in prevalence were associated with 
diﬃ  culties feeding, crying, or breathing after birth (OR 10·23, 95% CI 5·85–17·88; p<0·0001); abnormal antenatal 
periods (2·15, 1·53–3·02; p<0·0001); and head injury (1·97, 1·28–3·03; p=0·002). In adults (aged ≥18 years), the 
disorder was signiﬁ cantly associated with admission to hospital with malaria or fever (2·28, 1·06–4·92; p=0·036), 
exposure to T canis (1·74, 1·27–2·40; p=0·0006), exposure to T gondii (1·39, 1·05–1·84; p=0·021), and exposure to 
O volvulus (2·23, 1·56–3·19; p<0·0001). Hypertension (2·13, 1·08–4·20; p=0·029) and exposure to T solium (7·03, 
2·06–24·00; p=0·002) were risk factors for adult-onset disease. 
Interpretation The prevalence of active convulsive epilepsy varies in sub-Saharan Africa and that the variation is probably 
a result of diﬀ erences in risk factors. Programmes to control parasitic diseases and interventions to improve antenatal 
and perinatal care could substantially reduce the prevalence of epilepsy in this region. 
Funding Wellcome Trust, University of the Witwatersrand, and South African Medical Research Council.
Introduction 
Epilepsy is one of the most common neurological 
conditions worldwide. The prevalence of epilepsy is 
highest in poor countries1 and in rural areas,2 particularly 
in sub-Saharan Africa.3 Reported prevalence varies 
between studies in sub-Saharan Africa,3 but the cause of 
this variation is unknown. Diﬀ erences in methodology 
and case deﬁ nition could partly explain this heterogeneity, 
but the epidemiology of parasitic diseases (particularly 
malaria,4 cysticercosis,5–8 onchocerciasis,9,10 toxocariasis,6,11 
and toxoplasmosis12), perinatal events,13 head injuries,14 
HIV infection,15 and hereditary factors16 might also 
contribute. Previous studies in sub-Saharan Africa have 
focused on a small number of risk factors in areas with 
high prevalence of epilepsy,3 but none have examined a 
wide range of potential risk factors. We established the 
prevalence of active convulsive epilepsy and its risk factors 
in sub-Saharan Africa, and assessed the relative 
contributions of parasitic and non-parasitic risk factors for 
epilepsy in this region. 
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Methods
Study design 
We did large population-based cross-sectional and case-
control studies in ﬁ ve Health and Demographic 
Surveillance System (HDSS) centres that are part of the 
International Network for the Demographic Evaluation of 
Populations and Their Health (INDEPTH). Surveys were 
done in Kiliﬁ , Kenya (Dec 3, 2007–July 31, 2008); Agincourt, 
South Africa (Aug 4, 2008–Feb 27, 2009); Iganga-Mayuge, 
Uganda (Feb 2, 2009–Oct 30, 2009); Ifakara, Tanzania 
(May 4, 2009–Dec 31, 2009); and Kintampo, Ghana (Aug 2, 
2010–April 29, 2011). We selected these centres because of 
the endemicity of parasitic diseases associated with 
epilepsy, availability of health facilities able to provide 
support to people with epilepsy, and logistics.
All aspects of the study were approved by the ethics 
committees of University College London and the 
London School of Hygiene and Tropical Medicine, and 
by the ethics review boards in each of the participating 
countries. All participants or guardians gave written 
informed consent.
Participants and procedures 
We used a three-stage screening process to identify cases 
of active convulsive epilepsy.14 In the ﬁ rst stage, two 
screening questions were asked during a routine, door-
to-door census organised by each HDSS centre. Heads of 
households were interviewed about whether any 
residents had had convulsions. In the second stage, 
trained lay ﬁ eldworkers administered a detailed 
questionnaire17 (appendix) to individuals identiﬁ ed as 
having a history of convulsions in stage one. Individuals 
whose responses to the questionnaire suggested they 
might have epilepsy were examined during stage three 
by clinicians who made a ﬁ nal diagnosis. 
To enable comparison between our three-stage method 
and the two-stage surveys used in other population-based 
studies in Africa,18–22 we selected a random population 
sample from each centre’s census database with the 
RAND() command in MySQL (Oracle, Redwood Shores, 
CA, USA). The questionnaire17 used in the second stage 
of the study was administered to this randomly sampled 
population; individuals identiﬁ ed as possibly having 
epilepsy after the questionnaire results were assessed 
clinically in stage three.
We studied only convulsive epilepsies, because 
convulsions are the most reliably detected and reported 
symptom, and are associated with the greatest morbidity 
(eg, burns and stigma) and mortality.23 Active convulsive 
epilepsy was deﬁ ned as two or more unprovoked 
convulsive seizures (which could be primarily or 
secondarily generalised) occurring at least 24 h apart, 
with at least one seizure in the preceding 12 months.14,24 
For each case, an age-matched control individual was 
randomly selected from the relevant centre’s census 
database with the RAND() command. The control 
individuals were frequency matched by age groups: 
0–5 years, 6–12 years, 13–18 years, 19–28 years, 
29–49 years, and 50 years or older. In the case-control 
study, two or three control individuals were selected to 
compensate for non-response and ensure balance in the 
number of cases and control individuals at each centre. 
All control individuals were assessed by a clinician to 
conﬁ rm that they did not have epilepsy.  
Fieldworkers then administered questionnaires based 
on those used in previous studies25–27 to individuals 
identiﬁ ed as having epilepsy and control individuals. 
Fieldworkers, who were masked to the status (case or 
control) of the person they were interviewing, gathered 
data on sociodemographic variables and historical risk 
Population Screened 
in stage 
one
Identiﬁ ed 
during 
screening 
in stage 
one
Screened 
in stage 
two*
Identiﬁ ed 
in stage 
two
Screened 
in stage 
three*
Diagnosed 
in stage 
three
Crude 
prevalence 
per 1000 
people
Prevalence 
per 1000 
people 
adjusted for 
attrition
Prevalence per 
1000 people 
adjusted for 
attrition and 
sensitivity
Prevalence 
ratios†
Age-
standardised 
prevalence per 
1000 people‡
Kiliﬁ , Kenya 233 881 232 176 
(99·3%)
5152 
(2·2%)
4886 
(94·8%)
1123 
(23·0%)
948 
(84·4%)
699 
(73·7%)
3·0 (2·8–3·2) 3·8 (3·5–4·0) 7·8 (7·5–8·2) 1·0 (NA) 7·4 (7·1–7·8)
Agincourt, 
South Africa 
83 121 82 818 
(99·6%)
546 
(0·7%)
515 
(94·3%)
354 
(68·7%)
328 
(92·7%)
245 
(74·7%)
3·0 (2·6–3·3) 3·4 (3·0–3·8) 7·0 (6·2–7·4) 0·9 (0·8–1·1) 8·1 (7·5–8·7)
Iganga-
Mayuge, 
Uganda
69 186 64 172 
(92·8%)
4917 
(7·7%)
3145 
(64·0%)
500 
(15·9%)
321 
(64·2%)
152 
(47·4%)
2·4 (2·0–2·8) 5·0 (4·4–5·6) 10·3 (9·5–11·1) 1·8 (1·7–1·9) 6·8 (6·2–7·5)
Ifakara, 
Tanzania
104 889 93 645 
(89·3%)
1389 
(1·5%)
1321 
(95·1%)
528 
(40·0%)
481 
(91·1%)
366 
(76·1%)
3·9 (3·5–4·3) 7·2 (6·5–7·8) 14·8 (13·8–15·4) 1·4 (1·3–1·5) 15·5 (14·7–16·3)
Kintampo, 
Ghana
129 812 113 796 
(87·7%)
3344 
(2·9%)
3046 
(91·1%)
570 
(18·7%)
443 
(77·7%)
249 
(56·2%)
2·2 (1·9–2·5) 4·9 (4·4–5·3) 10·1 (9·5–10·7) 0·8 (0·8–0·9) 10·1 (9·5–10·7)
Overall 620 889 586 607 
(94·5%)
15 348 
(2·6%)
12 913 
(84·1%)
3075 
(23·8%)
2521 
(82·0%)
1711 
(67·9%)
·· ·· ·· ·· ··
Data in parentheses are % or 95% CI. NA=not applicable. *Expressed as a percentage of the total identiﬁ ed during screening in the preceding stage. †On the basis of estimates adjusted for attrition and sensitivity; 
p=0·006. ‡Standardised to the age distribution of the US population in 2000 (based on estimates adjusted for attrition and sensitivity of the three-stage method).
Table 1: Prevalence of active convulsive epilepsy in ﬁ ve centres in sub-Saharan Africa
See Online for appendix
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factors (perinatal events, head injuries, and diet). Clinical 
history was also obtained by masked, trained clinicians 
(the same clinicians who made initial diagnoses) and 
they made a diagnosis of active convulsive epilepsy. 
When the study participants were younger than 
18 years or had cognitive impairment, the mother or 
caregiver was interviewed. The questionnaires ad-
ministered to mothers or caregivers included questions 
about antenatal (eg, severe abdominal pain, vaginal 
bleeding, or infection during pregnancy) and perinatal 
events (diﬃ  culties breathing, feeding, or crying after 
birth, as recalled by the mother or caregiver28). Questions 
about consumption of alcohol and use of recreational 
drugs were administered to adult participants only. 
Blood samples were taken from a subgroup of 
300 participants with epilepsy and 300 control 
individuals from each centre who were randomly 
selected with the RAND() command. This sample size 
would allow detection of an odds ratio (OR) greater than 
2·4, with 80% power and the assumption that 5% of 
control individuals had epilepsy. The samples were 
screened for antibodies to Toxocara canis, Toxoplasma 
gondii, Onchocerca volvulus, Plasmodium falciparum, 
Taenia solium, and HIV. Exposure was established by 
detection of IgG antibodies to the parasitic antigens. IgG 
antibodies against T canis were detected with a 
commercial kit (Toxocara IgG-ELISA, Cypress 
Diagnostics, Belgium; sensitivity 97%; speciﬁ city 78%). 
Anti-Toxocara IgG4 antibodies with an optical density 
greater than the cutoﬀ  (mean plus three standard 
deviations of 30 IgG-negative serum samples) were 
interpreted as positive. IgG antibodies against T gondii 
were detected with a commercial kit (Toxoplasma IgG-
ELISA, Genesis Diagnostics, Ely, UK; 100% agreement 
with test samples) and were judged positive when optical 
density was greater than that of the positive 8 IU/mL 
sample in the kit. Exposure to O volvulus was established 
with a modiﬁ cation of an ELISA that detects IgG4 to the 
recombinant antigen Ov-16GST (sensitivity 90%; 
speciﬁ city 98%).29 A sample with an optical density 
greater than the cutoﬀ  (mean plus three standard 
deviations of 30 serum samples from the Agincourt 
HDSS, where onchocerciasis is not prevalent) were 
interpreted as positive. Exposure to malaria was 
established with an in-house ELISA30 that tests for IgG 
antibodies to crude schizont extract from a P falciparum 
A4 clone line, which is derived from a laboratory strain. 
Exposure to the larval stage (cysticercosis) and adult 
Figure: Age-speciﬁ c prevalence and age at onset of active convulsive epilepsy in the ﬁ ve centres
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stage (taeniasis) of the parasite T solium was established 
with a western blot (sensitivity 97%; speciﬁ city 99%; 
detection of cases with two or more viable cysts in the 
brain) and antibodies to taeniasis (RES33 antigen; 
sensitivity 99%; speciﬁ city 93%).31 IgG antibodies to HIV 
type 1 or type 2, or both, were detected with the fourth-
generation screening test Vironostika HIV Uniform II 
Ag/Ab (BioMerieux, France) according to the 
manufacturer’s instructions. 
Statistical analysis
We double entered and veriﬁ ed all data in the MySQL 
open-source database (version 5; Oracle Corporation, 
Redwood Shores, CA, USA). All statistical analyses were 
done in STATA (version 12). 
We estimated an unadjusted prevalence of the disorder 
with 95% CIs for each centre by dividing the number of 
cases conﬁ rmed in stage three by the total number of 
individuals screened in stage one. We used multiple 
imputation32,33 to reduce bias because of attrition between 
stages of the survey. Imputation (using the ice command 
in Stata) was done separately for each centre and ﬁ ve 
imputed datasets were created.32,34 We further adjusted 
prevalence estimates by dividing by the estimated 
sensitivity (0·486 for the three-stage method; 0·767 for 
the two-stage method).35 To account for diﬀ erences in age 
distribution between study centres, we produced age-
standardised, centre-speciﬁ c prevalence estimates, with 
the age distribution of the US population in 2000 as 
reference.36 We used the US population to enable 
comparison between our study and others in countries of 
low and middle income, in which the US population has 
been used for adjustment. We used a logistic regression 
model to test for heterogeneity between study centres 
after adjusting for age and sex. 
For the case-control study, adjusted ORs were obtained 
by ﬁ tting logistic regression models that included age, 
sex, education (none, primary, or secondary and above), 
employment, marital status, and country as covariates as 
well as the risk factor of interest. Age was modelled as a 
fractional polynomial of degree two.37 In models ﬁ tted to 
data for children, the marital status of the mother and 
employment status of the mother and father were 
included as covariates. For variables for which an event 
date was available (head injuries in adults and hospital 
admissions for malaria or fever in adults and children), 
events after the seizure date or after an index date in 
control individuals were excluded. We selected index 
dates for each control individual by randomly sampling 
the dates of ﬁ rst seizure in individuals with epilepsy 
from the same age group with the bsample command in 
STATA. 
Nutritional status was established with age-speciﬁ c 
height and weight.38 Adults (older than 19 years) with a 
body-mass index less than 18·5 kg/m², adolescents (aged 
10–19 years) with body-mass-index-for-age Z scores of less 
than –2, and children (younger than 10 years) with weight-
for-height or height-for-age Z scores of less than –2 were 
deemed to be malnourished. All Z scores were computed 
with the zanthro command in Stata. The 2000 US growth 
charts were used as the reference distribution.39
Participants 
screened
Prevalence per 
1000 people 
(95% CI)*
Univariable analysis Multivariable analysis
Prevalence 
ratio (95% CI)
p value Prevalence 
ratio (95% CI)
p value
Kiliﬁ , Kenya
Sex
Female 123 914 7·0 (6·6–7·5) 1·0 (NA) <0·0001 1·0 (NA) 0·0004
Male 108 262 8·6 (8·1–9·2) 1·3 (1·1–1·5) ·· 1·3 (1·1–1·4) ··
Age (years)
0–5 41 868 6·3 (5·6–7·1) 1·0 (NA) <0·0001 1·0 (NA) 0·0007
6–12 52 248 7·4 (6·7–8·2) 1·2 (1·3–1·8) ·· 1·2 (0·9–1·5) ··
13–18 34 228 10·3 (9·2–11·4) 1·6 (1·5–1·8) ·· 1·6 (1·3–2·1) ··
19–28 37 523 9·7 (8·7–10·7) 1·6 (1·4–1·4) ·· 1·6 (1·3–2·0) ··
29–49 42 269 6·0 (5·3–6·8) 1·0 (0·9–1·1) ·· 1·0 (0·8–1·3) ··
≥50 24 040 7·5 (6·4–8·7) 1·1 (1·0–1·2) ·· 1·1 (0·8–1·5) ··
Agincourt, South Africa
Sex
Female 43 065 6·6 (5·3–7·6) 1·0 (NA) 0·369 1·0 (NA) 0·086
Male 39 753 7·6 (6·2–8·6) 1·1 (0·9–1·4) ·· 1·2 (1·0–1·6) ··
Age (years)
0–5 11 531 2·1 (0·8–3·3) 1·0 (NA) <0·0001 1·0 (NA) 0·0003
6–12 13 044 4·7 (3·1–6·4) 2·4 (1·2–4·8) ·· 2·6 (1·3–5·3) ··
13–18 12 341 6·2 (4·3–8·2) 3·2 (1·7–6·3) ·· 3·2 (1·6–6·4) ··
19–28 17 770 6·4 (4·7–8·2) 3·3 (1·7–6·3) ·· 3·1 (1·5–6·0) ··
29–49 18 491 10·9 (8·8–13·2) 5·5 (3·0–10·3) ·· 5·5 (2·8–10·5) ··
≥50 9641 9·5 (7·6–11·5) 4·9 (2·5–9·5) ·· 4·7 (2·3–9·4) ··
Iganga-Mayuge, Uganda
Sex
Female 32 518 8·9 (8·0–10·0) 1·0 (NA) 0·871 1·0 (NA) 0·189
Male 31 625 9·6 (8·5–10·7) 1·0 (0·8–1·3) ·· 1·3 (0·9–1·7) ··
Age (years)
0–5 11 444 18·7 (14·4–23·3) 1·0 (NA) <0·0001 1·0 (NA) 0·0001
6–12 14 972 11·3 (8·6–14·2) 0·5 (0·4–0·7) ·· 0·9 (0·9–1·4) ··
13–18 10 722 7·2 (4·3–9·9) 0·3 (0·2–0·5) ·· 0·8 (0·5–1·4) ··
19–28 10 509 6·2 (3·5–8·8) 0·3 (0·2–0·5) ·· 0·6 (0·4–1·1) ··
29–49 11 765 3·9 (2·1–5·8) 0·2 (0·1–0·3) ·· 0·3 (0·2–0·6) ··
≥50 4740 3·9 (0·8–7·2) 0·2 (0·1–0·4) ·· 0·2 (0·1–0·7) ··
Ifakara, Tanzania
Sex
Female 44 694 14·0 (12·1–15·8) 1·0 (NA) 0·191 1·0 (NA) 0·467
Male 44 245 10·9 (10·9–14·0) 0·9 (0·8–1·1) ·· 0·9 (0·8–1·1) ··
Age (years)
0–5 21 028 8·8 (7·6–10·2) 1·0 (NA) <0·0001 1·0 (NA)  0·0002
6–12 17 655 13·2 (11·5–15·0) 1·4 (1·1–1·8) ·· 2·1 (1·4–3·1) ··
13–18 9383 19·8 (17·0–22·9) 2·2 (1·7–3·0) ·· 3·8 (2·6–5·5) ··
19–28 13 223 13·4 (11·4–15·6) 1·4 (1·0–1·9) ·· 2·4 (1·6–3·5) ··
29–49 21 866 13·2 (11·7–14·8) 1·4 (1·1–1·8) ·· 2·0 (1·4–2·9) ··
≥50 10 272 16·5 (14·0–19·2) 1·8 (1·4–2·5) ·· 1·0 (0·6–1·7) ··
(Continues on next page)
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Population attributable fractions (PAFs) were estimated 
separately for every risk factor and for combinations of 
risk factors with the user-written command punacc, 
which implements the method of Greenland and 
Drescher.40 No adjustment for multiple comparisons was 
made, because this adjustment can lead to errors of 
interpretation when strong previous evidence of 
association is available for several risk factors.41 
Role of the funding source 
The sponsors had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study and 
the corresponding author had ﬁ nal responsibility for the 
decision to submit for publication.
Results 
586 607 residents in the study areas were screened in 
stage one, of whom 1711 were diagnosed as having 
active convulsive epilepsy by the end of stage three 
(table 1). The proportion of individuals identiﬁ ed as 
having convulsive seizures in stage one was highest in 
Iganga-Mayuge, Uganda, and lowest in Agincourt, 
South Africa (table 1). The ﬁ nal crude prevalence was 
highest in Ifakara, Tanzania, and was lowest in 
Kintampo, Ghana (table 1). After adjustment for 
attrition between stages one and two, and between 
stages two and three, by multiple imputation, we noted 
that prevalence doubled in Iganga-Mayuge and in 
Kintampo, and increased by more than 1·5 times in 
Ifakara (table 1). After adjustment for both attrition and 
sensitivity of the three-stage method, prevalence was 
lowest in Agincourt and highest in Ifakara, with a 
signiﬁ cant diﬀ erence between the two (table 1). The 
age-standardised prevalence was lowest in Iganga-
Mayuge and highest in Ifakara (table 1).  
Age-speciﬁ c prevalence varied between centres (ﬁ gure). 
In all centres, most cases of epilepsy occurred in children 
(ﬁ gure). Prevalence in Kiliﬁ , Kenya, was 30% higher in 
male residents than in female ones and 60% higher in 
adolescents and young adults aged 13–28 years than in 
the youngest age group (0–5 years; table 2). In Kintampo, 
prevalence was marginally higher in male residents than 
in female ones, and varied signiﬁ cantly with age (table 2). 
In the other centres, prevalence varied by age but not by 
sex (table 2). 
Prevalence estimates from the two-stage method were 
20–49% higher than those from the three-stage method 
for Kiliﬁ , Agincourt, Kintampo, and Iganga-Mayuge 
when the data were adjusted for attrition between stages 
and sensitivity of the screening methods (appendix). In 
Ifakara, adjusted prevalence was higher with the three-
stage than the two-stage method (appendix).
The 1711 individuals identiﬁ ed as having active 
convulsive epilepsy in stage three and 2032 control 
individuals were given questionnaires to assess risk 
factors (tables 3, 4). 1659 control individuals refused to 
Control 
individuals*
Individuals with 
active convulsive 
epilepsy†
Odds ratio 
(95% CI)‡
p value
Seizures in the family 122/1028 (11·9%) 153/825 (18·5%) 1·72 (1·31–2·25) <0·0001
Maternal seizures 9/1031 (0·9%) 19/822 (2·3%) 2·84 (1·24–6·49) 0·013
Abnormal delivery 39/1006 (3·9%) 47/816 (5·8%) 1·56 (0·98–2·47) 0·061
Abnormal antenatal period 66/1004 (6·6%) 118/797 (14·8%) 2·15 (1·53–3·02) <0·0001
Home delivery 510/1007 (50·6%) 497/819 (60·7%) 1·24 (0·97–1·57) 0·081
Diﬃ  culties feeding, crying, 
or breathing
16/1003 (1·6%) 96/794 (12·1%) 10·23 (5·85–17·88) <0·0001
Any other problems after 
birth
35/1014 (3·5%) 86/816 (10·5%) 2·77 (1·82–4·23) <0·0001
Head injury 46/1025 (4·5%) 66/822 (8·0%) 1·97 (1·28–3·03) 0·002
Malnourished 194/952 (20·4%) 163/752 (21·7%) 1·00 (0·78–1·29) 0·992
Eats cassava 751/1029 (73·0%) 625/825 (75·8%) 0·99 (0·77–1·26) 0·913
Dogs in household 512/1031 (49·7%) 340/826 (41·2%) 0·91 (0·73–1·15) 0·441
Cats in household 502/1029 (48·8%) 403/823 (49·0%) 1·26 (0·98–1·62) 0·066
Eats pork 387/1025 (37·8%) 246/814 (30·2%) 0·99 (0·79–1·25) 0·939
Positive for malaria IgG 
(schizont)
491/610 (80·5%) 333/423 (78·7%) 1·14 (0·75–1·73) 0·535
Admitted to hospital with 
malaria or fever, or both
24/1036 (2·3%) 44/831 (5·3%) 2·01 (1·17–3·45) 0·011
Positive for Toxocara canis 
IgG4
123/510 (24·1%) 106/358 (29·6%) 1·19 (0·85–1·66) 0·316
Positive for Toxoplasma 
gondii IgG
150/599 (25·0%) 115/416 (27·6%) 1·15 (0·85–1·58) 0·367
Positive for Taenia solium 10/414 (2·4%) 5/243 (2·1%) 1·09 (0·34–3·45) 0·884
Positive for Onchocerca 
volvulus
61/414 (14·7%) 55/244 (22·5%) 1·67 (1·09–2·57) 0·019
HIV positive 50/606 (8·3%) 39/419 (9·3%) 1·28 (0·80–2·03) 0·304
Data are n/N (%), unless otherwise stated. N varies because data for each factor were obtained from varying numbers 
of participants. Data from all centres combined. *Total n=1036. †Total n=831. ‡Odds ratio adjusted for age, sex, 
mother’s education, mother’s marital status, employment of mother or father, and country.
Table 3: Risk factors for active convulsive epilepsy in children (aged <18 years) 
Participants 
screened
Prevalence per 
1000 people 
(95% CI)*
Univariable analysis Multivariable analysis
Prevalence 
ratio (95% CI)
p value Prevalence 
ratio (95% CI)
p value
(Continued from previous page)
Kintampo, Ghana
Sex
Female 57 880 9·1 (7·8–10·3) 1·0 (NA) 0·027 1·0 (NA) 0·057
Male 55 904 11·1 (9·7–12·3) 1·2 (1·0–1·4) ·· 1·2 (1·0–1·4) ··
Age (years)
0–5 17 424 12·1 (10·6–13·9) 1·0 (NA) <0·0001 1·0 (NA) 0·0009
6–12 23 121 9·7 (8·5–11·0) 0·8 (0·6–1·0) ·· 0·8 (0·6–1·0) ··
13–18 17 019 13·2 (11·5–15·0) 1·1 (0·9–1·5) ·· 1·1 (0·9–1·5) ··
19–28 18 843 15·2 (13·5–17·1) 1·2(1·0–1·6) ·· 1·2 (1·0–1·6) ··
29–49 23 091 6·6 (5·6–7·7) 0·5(0·4–0·7) ·· 0·5 (0·4–0·7) ··
≥50 14 286 3·3 (2·4–4·4) 0·2 (0·1–0·4) ·· 0·2 (0·1–0·4) ··
NA=not applicable. *On the basis of the number of cases estimated after adjustment for loss to follow-up and sensitivity 
of the screening method.
Table 2: Age-speciﬁ c and sex-speciﬁ c prevalence of active convulsive epilepsy by centre
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take part: 711 (57%) of 1238 in Kiliﬁ , 259 (50%) of 520 in 
Agincourt, 298 (55%) of 537 in Iganga-Mayuge, and 
391 (51%) of 772 in Kintampo (data from Ifakara are 
unavailable). Age matching resulted in a similar age 
distribution in case and control individuals (appendix). 
Individuals with active convulsive epilepsy were more 
likely to be male than were control individuals (51% vs 
46%; p=0·003) and to have had no education (38% vs 
32%; p<0·0001; appendix).  
For children (aged <18 years), factors related to their 
antenatal period and delivery were associated with the 
greatest relative increase in prevalence of epilepsy 
(table 3). Seizures in the family, maternal seizures, and 
head injuries were also strong risk factors (table 3). Of 
parasitic risk factors, exposure to O volvulus and hospital 
admission for malaria or fever, or both, were signiﬁ cantly 
associated with the disorder (table 3). 
Overall, parasitic risk factors were more strongly 
associated with active convulsive epilepsy in adults than 
in children (tables 3, 4). In adults, we recorded signiﬁ cant 
associations between the disorder and exposure to 
T canis and T gondii (table 4). The association between 
exposure to T solium and the disorder in adults was not 
signiﬁ cant (table 4), but we did record a strong 
association with adult-onset disease (table 5). Active 
convulsive epilepsy and HIV were not associated 
(tables 3, 4). Cassava consumption was associated with 
active convulsive epilepsy in adults but not in children 
(tables 3, 4). Hypertension was a signiﬁ cant risk factor 
for late-onset disease (table 5). 
Associations were generally consistent across study 
sites (appendix). However, the interaction with study site 
in children was signiﬁ cant for adverse perinatal events 
(p=0·0068) and a history of seizures in the family 
(p=0·0112). In adults, the interaction was signiﬁ cant for a 
history of seizures in the family (p=0·0096), cassava 
consumption (p=0·0008), pork consumption (p=0·0099), 
and alcohol consumption (p=0·0352).
With the exception of women who delivered their 
babies at home and participants who ate cassava or 
were  malnourished, the proportion of participants 
exposed to non-parasitic risk factors was generally low 
(<10%) across all ﬁ ve centres (appendix). Most of the 
population consumed cassava and home delivery was 
also very common, particularly in Kiliﬁ  (83% of control 
individuals; 81% of case individuals) and Kintampo 
(86% of control individuals; 85% of case individuals; 
appendix). Malnutrition was prevalent at all centres 
(10–36% of participants; appendix). Head injuries were 
common among children in Kintampo (19% of control 
individuals; 23% of case individuals), but less so 
elsewhere (appendix). 
Prevalence of parasitic risk factors was higher than was 
that of non-parasitic risk factors, especially in adults 
(appendix). However, we recorded substantial variation 
between centres: in adults, the proportion of control 
individuals exposed to O volvulus ranged from 9% in 
Iganga-Mayuge to 38% in Ifakara, to T gondii from 11% 
in Agincourt to 67% in Kintampo, and to T canis from 8% 
in Agincourt to 62% in Ifakara (appendix).  
The associations between parasitic risk factors and focal 
active convulsive epilepsy in adults were of similar 
magnitude to those recorded for active convulsive 
epilepsy (appendix). 
The PAFs for non-parasitic risk factors were generally 
low (tables 6, 7), although the total PAF associated with 
risk factors related to the antenatal and perinatal periods 
in children was 33% across all centres (table 6). PAFs for 
the parasitic risk factors were higher in adults than 
children (except hospital admission for malaria) and 
varied substantially between the centres (tables 6, 7). The 
combined PAF for parasitic risk factors in adults varied 
from 9% in Agincourt to 62% in Ifakara (table 7). 
Discussion
We have shown that the prevalence of active convulsive 
epilepsy varies between ﬁ ve large populations in sub-
Saharan Africa (panel). The variation is unlikely to have 
been caused by diﬀ erences in method, because we used 
Control 
individuals*
Individuals with active 
convulsive epilepsy†
Odds ratio 
(95% CI)‡
p value
Seizures in the family 106/987 (10·7%) 180/869 (20·7%) 2·30 (1·73–3·07) <0·0001
Maternal seizures 3/992 (0·3%) 11/873 (1·3%) 3·02 (0·75–12·14) 0·120
Abnormal delivery 37/898 (4·1%) 33/852 (3·9%) 1·11 (0·65–1·89) 0·706
Home delivery 571/841 (67·9%) 593/832 (71·3%) 1·18 (0·92–1·53) 0·196
Problems after birth 13/891 (1·5%) 62/841 (7·4%) 6·41 (3·28–12·53) <0·0001
Head injury 18/996 (1·8%) 35/880 (4·0%) 2·29 (1·22–4·30) 0·010
Malnourished 127/960 (13·2%) 138/834 (16·5%) 1·25 (0·93–1·67) 0·138
Drinks alcohol 200/957 (20·9%) 143/855 (16·7%) 0·88 (0·67–1·15) 0·351
Eats cassava 750/991 (75·7%) 712/871 (81·7%) 1·46 (1·12–1·91) 0·005
Dogs in household 469/993 (47·2%) 356/875 (40·7%) 0·89 (0·71–1·12) 0·316
Cats in household 457/992 (46·1%) 403/876 (46·0%) 1·03 (0·80–1·32) 0·832
Eats pork 403/986) (40·9%) 348/873 (39·9%) 1·10 (0·89–1·36) 0·387
Uses drugs 73/963 (7·6%) 63/853 (7·4%) 1·21 (0·81–1·79) 0·357
Hypertension 21/983 (2·1%) 27/870 (3·1%) 1·74 (0·91–3·33) 0·094
Stroke 5/982 (0·5%) 10/872 (1·1%) 1·94 (0·61–6·15) 0·258
Diabetes mellitus 3/985 (0·3%) 6/873 (0·7%) 2·48 (0·56–10·87) 0·229
Positive for malaria IgG 
(schizont)
596/703 (84·8%) 473/563 (84·0%) 1·17 (0·75–1·81) 0·496
Admitted to hospital with 
malaria or fever, or both
11/996 (1·1%) 26/880 (3·0%) 2·28 (1·06–4·92) 0·036
Positive for Toxocara canis 
IgG4
160/611 (26·2%) 194/504 (38·5%) 1·74 (1·27–2·40) 0·0006
Positive for Toxoplasma 
gondii IgG
307/692 (44·4%) 265/555 (47·7%) 1·39 (1·05–1·84) 0·021
Positive for Taenia solium 8/421 (1·9%) 10/290 (3·4%) 1·98 (0·72–5·43) 0·183
Positive for Onchocerca 
volvulus
128/422 (30·3%) 147/291 (50·5%) 2·23 (1·56–3·19) <0·0001
HIV positive 132/698 (18·9%) 101/558 (18·1%) 0·85 (0·61–1·18) 0·334
Data are n/N (%), unless otherwise stated. Data from all centres combined. *Total n=996. †Total n=880. ‡Odds ratio 
adjusted for age, sex, education, marital status, employment, and country. 
Table 4: Risk factors for active convulsive epilepsy in adults (aged ≥18 years) 
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the same screening methods, techniques, and deﬁ nitions 
in all sites24,44 to minimise the methodological component 
of heterogeneity reported in a meta-analysis of prevalence 
studies.2 The variation is probably a result of diﬀ erences 
in risk factors. Risk factors related to the antenatal and 
perinatal periods were the most strongly associated with 
active convulsive epilepsy in children. Parasitic risk 
factors were strongly associated with active convulsive 
epilepsy in adults, but we recorded substantial variability 
between centres. Our multicentre study used well 
established health and demographic surveillance 
infrastructures, which allowed rapid and eﬃ  cient 
screening of large populations. 
The crude prevalence estimates from the three-stage 
method were lower than were those from the two-stage 
method in four centres. This diﬀ erence could be partly 
attributed to the ﬁ rst stage of the three-stage method, 
which contributed more than 80% of false negatives in 
the validation study.35 False negatives in stage one were 
probably a result of stigma-related concealment of 
seizures, as was recorded in Kiliﬁ ,35 or possibly poor 
awareness of seizures in the family by key informants 
(ie, household heads).45 
Our estimates conﬁ rm that prevalence of active 
convulsive epilepsy in sub-Saharan Africa is high and is 
within the range estimated for active epilepsy in 
countries of low and middle income,2 although previous 
estimates might include ﬁ ndings for non-convulsive 
epilepsies.2 Cross-sectional studies are thought to 
underestimate the prevalence of lifetime epilepsy by 
75%, and non-convulsive epilepsy might constitute up to 
50% of all epilepsies in population-based studies.46 
Therefore, our estimates probably represent a quarter of 
all types of epilepsy in this region. The only other study 
of active convulsive epilepsy in this region (done in 
Kiliﬁ ) estimated a prevalence of 4·5 per 1000 people.14 
This value was an underestimate, because the 
investigators did not adjust for the sensitivity of the 
entire three-stage method, although the crude prevalence 
was similar to that in our study. Our estimates varied by 
age and study centre, which reﬂ ects the diﬀ erence in 
prevalence of risk factors. 
Genetic susceptibility to epilepsy is well documented47,48 
and could explain the strong association with family 
history that we recorded. Family members could also 
share other non-genetic risk factors—eg, parasitic or 
perinatal risk factors. However, the eﬀ ect of family 
history is potentially overestimated, because people with 
active convulsive epilepsy might be more aware of other 
family members who are aﬀ ected by seizures than are 
individuals who do not have epilepsy. 
Antenatal diﬃ  culties are associated with epilepsy.49 
Birth asphyxia is a risk factor for epilepsy and neonatal 
mortality, but is preventable.28 In a 2005 review of simple 
inter ventions aimed at low-income countries, Darmstadt 
and colleagues50 showed that 43–73% of neonatal deaths 
in Africa could be prevented with implementation of a 
package of interventions to improve antenatal and 
peri natal care. The implementation of these interventions 
would probably aﬀ ect the prevalence of epilepsy in this 
region.  
Both malnutrition and cassava consumption were 
positively associated with epilepsy in adults in our study. 
These two risk factors are related; diets in which cassava 
is a staple are common in poor areas where malnutrition 
is widespread. Other epidemiological studies have also 
reported positive associations between epilepsy and 
malnutrition.38,51 Biochemical mechanisms whereby 
malnutrition (particularly protein malnutrition) could 
lower the seizure threshold are known,52 but malnutrition 
is more likely to be a result of epilepsy than a cause. 
Additionally, parasitic infection could play a part as either 
a mediator or confounder of the relation between 
epilepsy and malnutrition. 
The association between head injuries and active 
convulsive epilepsy was weaker than has been reported 
Control 
individuals*
Individuals with 
adult-onset active 
convulsive epilepsy†
Odds ratio 
(95% CI)‡
p value
Seizures in the family 106/987 (10·7%) 62/299 (20·7%) 2·45 (1·66–3·62) <0·0001
Maternal seizures 3/992 (0·3%) 4/300 (1·3%) 4·69 (0·68–32·33) 0·117
Abnormal delivery 37/898 (4·1%) 8/287 (2·8%) 0·84 (0·36–1·96) 0·685
Home delivery 571/841 (67·9%) 210/278 (75·5%) 0·99 (0·68–1·46) 0·976
Problems after birth 13/891 (1·5%) 10/281 (3·6%) 3·46 (1·36–8·78) 0·009
Head injury 35/996 (3·5%) 23/304 (7·6%) 2·00 (1·07–3·76) 0·030
Malnourished 127/960 (13·2%) 52/291 (17·9%) 1·21 (0·82–1·80) 0·343
Drinks alcohol 200/957 (20·9%) 79/299 (26·4%) 0·99 (0·70–1·40) 0·958
Eats cassava 750/991 (75·7%) 231/302 (76·5%) 1·21 (0·85–1·73) 0·287
Dogs in household 469/993 (47·2%) 123/301 (40·9%) 0·99 (0·71–1·37) 0·936
Cats in household 457/992 (46·1%) 142/303 (46·9%) 1·21 (0·84–1·75) 0·297
Eats pork 403/986 (40·9%) 129/302 (42·7%) 1·07 (0·79–1·44) 0·679
Uses drugs 73/963 (7·6%) 32/295 (10·8%) 1·11 (0·67–1·82) 0·690
Hypertension 21/983 (2·1%) 21/301 (7·0%) 2·13 (1·08–4·20) 0·029
Stroke 5/982 (0·5%) 6/300 (2·0%) 1·90 (0·54–6·73) 0·321
Diabetes mellitus 3/985 (0·3%) 5/301 (1·7%) 2·70 (0·60–12·08) 0·194
Positive for malaria IgG 
(schizont)
596/703 (84·8%) 168/201 (83·6%) 1·29 (0·71–2·36) 0·402
Admitted to hospital with 
malaria or fever, or both
17/996 (1·7%) 11/304 (3·6%) 3·27 (1·37–7·82) 0·008
Positive for Toxocara canis 
IgG4
160/611 (26·2%) 58/176 (33·0%) 1·76 (1·09–2·84) 0·02
Positive for Toxoplasma 
gondii IgG
307/692 (44·4%) 97/195 (49·7%) 1·34 (0·89–2·01) 0·158
Positive for Taenia solium 8/421 (1·9%) 9/99 (9·1%) 7·03 (2·06–24·00) 0·002
Positive for Onchocerca 
volvulus
128/422 (30·3%) 47/98 (48·0%) 2·10 (1·24–3·57) 0·006
HIV positive 132/698 (18·9%) 42/199 (21·1%) 0·93 (0·59–1·46) 0·751
Data are n/N (%), unless otherwise stated. Data from all centres combined. For adult-onset cases, the ﬁ rst seizure 
occurs later, so we used an index date for control individuals that was diﬀ erent from that in other analyses. *Total 
n=996. †Onset when older than 18 years; total n=304. ‡Odds ratio adjusted for age, sex, education, marital status, 
employment, and country.
Table 5: Risk factors for adult-onset active convulsive epilepsy 
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in other African studies.14,53 Unlike our study, previous 
investigations might have involved assessment of head 
injuries before and after the ﬁ rst seizure, so the strength 
of these associations could be attributable to injuries 
occurring after the onset of epilepsy (ie, reverse causality), 
thereby overestimating the causal eﬀ ect.54 
Hypertension was positively associated with epilepsy in 
our study, as in European studies.55,56 The prevalence of 
this risk factor was low in the communities that we 
studied, probably because hypertension is under-reported 
in sub-Saharan Africa.57 Hypertension might therefore 
have a much greater role than is suggested by our data, 
and could become important causes of epilepsy in the 
future, as a result of changes in lifestyle and the 
advancing epidemiological transition.  
Exposure to the parasites T gondii, T canis, and 
O volvulus signiﬁ cantly increased the risk of epilepsy in 
adults. These associations are consistent with ecological 
studies10 and meta-analyses of case-control studies.6,12,58,59 
Ecological studies have shown that the prevalence of 
epilepsy is positively correlated with both the prevalence 
of toxoplasmosis seropositivity and onchocerciasis, and 
meta-analyses have further established positive 
associations for all three parasitic infections. In the nine 
case-control studies analysed for onchocerciasis,58 the 
ORs reported varied substantially and the overall 
association was of borderline signiﬁ cance (p=0·06). All 
three parasite species have been found in the CNS, but 
this location is uncommon for T canis60 and O volvulus;61 
we cannot rule out the possibility that these associations 
have arisen through confounding (eg, poverty) or reverse 
causality (ie, people with epilepsy might have increased 
exposure to parasites). 
The relation between cysticercosis and active 
convulsive epilepsy is well established.6–8 Worldwide, 
cysticercosis is thought to be the main risk factor for 
late-onset epilepsy and is an important risk factor for 
focal epilepsy in children.5,6 We did not record an 
association between cysticercosis and active convulsive 
epilepsy in either adults or children, although we did 
note a strong association with adult-onset epilepsy. This 
ﬁ nding might be explained by the low prevalence of the 
antibody to T solium, which will have lowered the 
statistical power to detect an association. By contrast, 
most African case-control studies that showed a 
signiﬁ cant association were done in settings where the 
prevalence of cysticercosis was much higher.5 Active 
convulsive epilepsy was not associated with HIV in our 
study, but individuals at risk of epilepsy because of an 
underlying condition caused by HIV will probably be 
selected against because of early mortality. Additionally, 
we did not record an association between exposure to 
malaria (as measured by antibodies to a schizont 
mixture) and active convulsive epilepsy, but were able 
All centres Kiliﬁ , Kenya Agincourt, South Africa Iganga-Mayuge, 
Uganda
Ifakara, Tanzania Kintampo, Ghana
Seizures in the family 0·08 (0·04 to 0·12) 0·07 (0·03–0·10) 0·06 (0·01 to 0·10) 0·09 (0·04–0·15) 0·06 (0·02 to 0·10) 0·14 (0·06 to 0·22)
Maternal seizures 0·01 (0 to 0·03) 0·01 (0 to 0·02) 0·02 (–0·01 to 0·05) 0·02 (0 to 0·05) 0·02 (0 to 0·04) 0·02 (–0·01 to 0·04)
Abnormal delivery 0·02 (0 to 0·04) 0·02 (0 to 0·05) 0·04 (–0·01 to 0·08) 0·01 (–0·01 to 0·03) 0·01 (0 to 0·02) 0·03 (–0·01 to 0·08)
Abnormal antenatal period 0·08 (0·04 to 0·11) 0·11 (0·06 to 0·16) 0·04 (0 to 0·08) 0·05 (0·02 to 0·09) 0·04 (0·01 to 0·06) 0·08 (0·02 to 0·13)
Home delivery 0·12 (–0·01 to 0·23) 0·16 (–0·02 to 0·32) 0·04 (–0·01 to 0·09) 0·05 (–0·01 to 0·10) 0·07 (–0·01 to 0·15) 0·15 (–0·02 to 0·29)
Diﬃ  culties feeding, crying, or breathing 0·11 (0·08 to 0·13) 0·07 (0·04 to 0·10) 0·11 (0·02 to 0·18) 0·06 (0·02 to 0·10) 0·10 (0·06 to 0·15) 0·34 (0·23 to 0·44)
Any other problems after birth 0·07 (0·04 to 0·09) 0·08 (0·05 to 0·12) 0·04 (0 to 0·08) 0·06 (0·02 to 0·10) 0·06 (0·02 to 0·09) 0·03 (0 to 0·06)
Head injury 0·04 (0·01 to 0·06) 0·04 (0·01 to 0·06) 0·02 (–0·01 to 0·04) 0·02 (0 to 0·05) 0·02 (0 to 0·03) 0·12 (0·03 to 0·19)
Malnourished 0 (–0·06 to 0·05) 0·00 (–0·07 to 0·06) 0 (–0·03 to 0·03) 0 (–0·06 to 0·06) 0 (–0·05 to 0·05) 0 (–0·03 to 0·03)
Cats in household 0·10 (0 to 0·20) 0·11 (–0·01 to 0·22) 0 (NA) 0 (0 to 0·01) 0·20 (–0·01 to 0·36) 0·07 (–0·01 to 0·15)
Positive for malaria IgG (schizont) 0·10 (–0·24 to 0·34) 0·07 (–0·17 to 0·26) 0·03 (–0·07 to 0·12) 0·12 (–0·32 to 0·42) 0·12 (–0·31 to 0·41) 0·12 (–0·32 to 0·42)
Admitted to hospital with malaria or 
fever, or both
0·03 (0·01 to 0·05) 0·04 (0·01 to 0·08) 0 (0 to 0) 0 (NA) 0·03 (0 to 0·06) 0 (NA)
Positive for Toxocara canis IgG4 0·05 (–0·05 to 0·13) 0·06 (–0·06 to 0·16) 0·02 (–0·02 to 0·05) 0·03 (–0·03 to 0·08) 0·09 (–0·09 to 0·24) 0·02 (–0·03 to 0·07)
Positive for Toxoplasma gondii IgG 0·04 (–0·04 to 0·11) 0·03 (–0·03 to 0·08) 0 (NA) 0·03 (–0·03 to 0·08) 0·06 (–0·07 to 0·17) 0·06 (–0·07 to 0·17)
Positive for Taenia solium 0 (–0·01 to 0·01) NA NA 0 (–0·02 to 0·02) 0 (–0·02 to 0·02) 0 (–0·04 to 0·04)
Positive for Onchocerca volvulus 0·06 (0·01 to 0·10) NA NA 0·05 (0 to 0·10) 0·09 (0·01 to 0·17) 0·14 (0·01 to 0·25)
HIV positive 0·02 (–0·02 to 0·06) 0·02 (–0·02 to 0·05) 0·02 (–0·02 to 0·05) 0·00 (–0·01 to 0·01) 0·02 (–0·02 to 0·07) 0·05 (–0·05 to 0·13)
Severe infections and parasites* 0·13 (0·01 to 0·24) 0·08 (–0·07 to 0·20) 0 (–0·03 to 0·04) 0·09 (–0·02 to 0·18) 0·27 (0·05 to 0·44) 0·22 (0·05 to 0·37)
Antenatal and perinatal risk factors 
combined†
0·33 (0·21 to 0·43) 0·39 (0·22 to 0·52) 0·22 (0·10 to 0·32) 0·18 (0·10 to 0·25) 0·25 (0·15 to 0·33) 0·51 (0·36 to 0·63)
Data in parentheses are 95% CIs. Risk factors with negative population attributable fraction (cassava consumption, dogs in the household, and pork consumption) are excluded from the table. NA=not available. 
*Combined population attributable fraction for admission to hospital with malaria or fever and positive for T canis, T gondii, T solium, or O volvulus. †Combined population attributable fraction for abnormal 
antenatal period; home delivery; diﬃ  culties feeding, crying, or breathing; and any other problems after birth.
Table 6: Population attributable fractions associated with each risk factor in children (aged <18 years)
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to conﬁ rm that severe malaria is a cause of epilepsy, as 
has been previously reported.4 
The estimated PAFs do not match the ORs, because 
they depend on the prevalence of the risk factor in 
individuals with the disorder as well as the OR. The 
cumulative PAF suggests that about 30% of paediatric 
epilepsy could be prevented with improvement of 
antenatal and perinatal care, and roughly 35% of adult 
epilepsy could be prevented with interruption of the 
transmission of parasites in sub-Saharan Africa. 
We used a three-stage, cross-sectional screening 
method that had low sensitivity for identiﬁ cation of 
potential cases of active convulsive epilepsy. In Iganga-
Mayuge, attrition between survey stages was high 
because of logistical diﬃ  culties with follow-up of eligible 
participants. However, we adjusted our estimates for 
these factors in our analyses. Additionally, the prevalence 
estimates from these studies might not be generalisable 
to many parts of sub-Saharan Africa, because the study 
sites were selected on the basis of endemicity of potential 
risk factors and availability of minimum resources 
necessary to support the studies.
The eﬀ ect estimates from our study should be 
cautiously interpreted, particularly those that are 
susceptible to recall bias (eg, perinatal risk factors) and 
measurement error (eg, under-reporting of diabetes). We 
could only establish exposure status before the onset of 
epilepsy for two risk factors (admission to hospital for 
malaria or fever, and head injuries). For many risk 
factors—eg, malnutrition, alcohol, and parasitic 
All centres Kiliﬁ , Kenya Agincourt, South Africa Iganga-Mayuge, 
Uganda
Ifakara, Tanzania Kintampo, Ghana
Seizures in the family 0·12 (0·08 to 0·15) 0·10 (0·06 to 0·13) 0·07 (0·04 to 0·11) 0·18 (0·07 to 0·27) 0·17 (0·10 to 0·23) 0·14 (0·08 to 0·20)
Maternal seizures 0·01 (0 to 0·02) 0·02 (0 to 0·04) 0·00 (0 to 0·01) 0·02 (–0·03 to 0·07) 0·00 (0 to 0·01) 0·00 (NA)
Abnormal delivery 0·00 (–0·01 to 0·02) 0·00 (–0·01 to 0·02) 0·00 (–0·02 to 0·02) 0·00 (–0·01 to 0·02) 0·00 (–0·01 to 0·02) 0·01 (–0·02 to 0·03)
Home delivery 0·11 (–0·06 to 0·25) 0·13 (–0·07 to 0·28) 0·08 (–0·04 to 0·18) 0·07 (–0·04 to 0·16) 0·10 (–0·05 to 0·24) 0·13 (–0·07 to 0·29)
Problems after birth 0·06 (0·04 to 0·08) 0·04 (0·02 to 0·06) 0·04 (0·01 to 0·06) 0·03 (–0·03 to 0·08) 0·02 (0 to 0·04) 0·17 (0·10 to 0·23)
Head injury 0·02 (0 to 0·04) 0·03 (0·01 to 0·06) 0·01 (0 to 0·02) 0·00 (0 to 0) 0·01 (0 to 0·02) 0·04 (0 to 0·07)
Malnourished 0·03 (–0·01 to 0·07) 0·03 (–0·01 to 0·07) 0·03 (–0·01 to 0·07) 0·07 (–0·03 to 0·16) 0·03 (–0·01 to 0·07) 0·04 (–0·01 to 0·09)
Cats in household 0·01 (–0·11 to 0·12) 0·01 (–0·12 to 0·14) 0·00 (–0·01 to 0·02) 0·00 (0 to 0) 0·02 (–0·22 to 0·22) 0·01 (–0·09 to 0·10)
Eats cassava 0·26 (0·09 to 0·40) 0·27 (0·09 to 0·41) 0·24 (0·08 to 0·37) 0·32 (0·11 to 0·47) 0·21 (0·07 to 0·33) 0·31 (0·11 to 0·47)
Eats pork 0·04 (–0·05 to 0·11) 0·02 (–0·03 to 0·08) 0·02 (–0·03 to 0·07) 0·02 (–0·03 to 0·07) 0·06 (–0·09 to 0·20) 0·05 (–0·06 to 0·15)
Uses drugs 0·01 (–0·01 to 0·04) 0·02 (–0·02 to 0·06) 0·01 (–0·01 to 0·02) 0·04 (–0·05 to 0·12) 0·01 (–0·01 to 0·02) 0·01 (–0·01 to 0·03)
Hypertension 0·01 (0 to 0·03) 0·01 (0 to 0·02) 0·05 (–0·01 to 0·10) 0·00 (NA to NA) 0·00 (0 to 0·01) 0·00 (NA)
Stroke 0·01 (0 to 0·01) 0·00 (0 to 0·01) 0·02 (–0·01 to 0·05) 0·00 (0 to 0) 0·00 (0 to 0·01) 0·00 (0 to 0)
Diabetes mellitus 0·00 (0 to 0·01) 0·00 (NA) 0·02 (–0·01 to 0·04) 0·00 (NA) 0·00 (0 to 0·01) 0·00 (NA)
Positive for malaria IgG (schizont) 0·12 (–0·27 to 0·39) 0·13 (–0·30 to 0·42) 0·06 (–0·13 to 0·22) 0·14 (–0·33 to 0·45) 0·14 (–0·32 to 0·44) 0·14 (–0·33 to 0·45)
Admitted to hospital with malaria or 
fever, or both
0·02 (0 to 0·03) 0·03 (0 to 0·06) 0·00 (0 to 0) 0·02 (–0·02 to 0·05) 0·02 (0 to 0·05) 0·00 (NA)
Positive for Toxocara canis IgG4 0·16 (0·08 to 0·24) 0·21 (0·10 to 0·31) 0·04 (0·01 to 0·07) 0·14 (0·03 to 0·25) 0·35 (0·17 to 0·50) 0·11 (0·04 to 0·18)
Positive for Toxoplasma gondii IgG 0·13 (0·02 to 0·23) 0·13 (0·02 to 0·22) 0·04 (0 to 0·08) 0·11 (0 to 0·20) 0·15 (0·02 to 0·26) 0·24 (0·04 to 0·40)
Positive for Taenia solium 0·01 (0 to 0·02) NA NA 0·02 (–0·03 to 0·07) 0·02 (–0·01 to 0·05) 0·01 (–0·01 to 0·04)
Positive for Onchocerca volvulus 0·14 (0·08 to 0·20) NA NA 0·07 (–0·01 to 0·14) 0·30 (0·17 to 0·41) 0·29 (0·16 to 0·40)
Severe infections and parasites* 0·35 (0·24 to 0·44) 0·31 (0·16 to 0·44) 0·09 (0·04 to 0·14) 0·28 (0·12 to 0·40) 0·62 (0·44 to 0·74) 0·52 (0·34 to 0·65)
Data in parentheses are 95% CIs. Risk factors with negative population attributable fraction (alcohol consumption, dogs in the household, and HIV positive) are excluded from the table. NA=not available. 
*Combined population attributable fraction for admission to hospital with malaria or fever and positive for T canis, T gondii, T solium, or O volvulus.
Table 7: Population attributable fractions associated with each risk factor in adults (aged ≥18 years)
Panel: Research in context
Systematic review
We searched Medline for reports published between Jan 1, 1966, and Dec 31, 2012, and 
Cochrane reviews published at any time, with the terms “epilepsy”, “prevalence”, and 
“Africa”. We restricted searches to titles and abstracts, and to human populations. We used 
no language restrictions. We identiﬁ ed 65 reports, of which ten were relevant; we had 
reviewed seven of these in a previous report.2 The estimated prevalence of epilepsy varied, 
ranging between 4·0 and 29·5 cases per 1000 people. In a second review, we searched the 
same databases, with the same date restrictions and no language restrictions, with the 
search terms “epilepsy”, “(developing countries OR low and middle income countries OR 
LMIC)”, and “(case control OR risk factors OR causes OR etiology)”. We identiﬁ ed 62 reports 
(including 16 that were relevant) and four reviews.3,5,42,43 Epilepsy had been previously 
associated with head injury, cerebrovascular disease, CNS infections and infestations 
(bacterial meningitis, viral encephalitis, malaria, neurocysticercosis, toxocariasis, and 
onchocerciasis), birth trauma, history of seizures, and family history of epilepsy. 
Interpretation
We have shown that the prevalence of active convulsive epilepsy varies widely across sub-
Saharan Africa and the variation is due to diﬀ erences in the distribution of risk factors. 
Most active convulsive epilepsy in adults is attributable to parasitic infestations, but 
perinatal causes were important in children. Interventions to reduce exposure to parasites 
and improve perinatal care could substantially reduce the burden of epilepsy in this region.
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infection—reverse causality is a potential source of bias. 
For parasitic risk factors, we used laboratory methods 
that establish exposure, but we could not detect direct 
parasite invasion of the CNS with techniques available in 
these sites. We adjusted for sociodemographic 
confounding factors, but residual confounding could 
remain—eg, individuals living in areas where parasites 
are common could be poorer and at higher risk of 
epilepsy than are those living in areas where parasites are 
less common. Additionally, we did not investigate some 
risk factors in this study (eg, brain tumours and other 
types of infection, particularly viral and bacterial)3 and 
some were only available for either adults or children (eg, 
data for perinatal events were obtained only for children).
In conclusion, the prevalence of active convulsive 
epilepsy varies across sub-Saharan Africa, and is related 
to the distribution and types of risk factors for epilepsy. 
Many cases of active convulsive epilepsy are attributable 
to parasitic disease, particularly in areas where 
onchocerciasis is common. Thus, parasitic-control 
programmes could reduce the prevalence of epilepsy. 
Furthermore, straightforward interventions aiming to 
improve antenatal and perinatal care could reduce the 
prevalence of epilepsy in sub-Saharan Africa. 
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